The Anti-Infectives Screening Core tests candidates, such as drugs, antibodies or peptides, against infectious diseases in vitro and in vivo. This core facilitates the process of early anti-infectives development by offering in vivo screening in murine models of infection, taking advantage of the specialized facilities and expertise available in the Department of Microbiology at NYU School of Medicine.

The Anti-Infectives Screening Core examines the activity of potential anti-infectives for four neglected diseases: Malaria, Chagas (South American Trypanosomiasis), Human African Trypanosomiasis and Leishmaniasis. However, incorporation of other infectious diseases that have murine models of infection would be contemplated in the future depending on the interests of internal and external users.